Federal health officials say the ultra-rare blood clots reported in six people who received Johnson & Johnson’s COVID-19 vaccine are similar to blood clots detected in a small number of people in Europe who were immunized with AstraZeneca’s shot.
The six cases in the U.S. were in women between the ages of 18 and 48. Women have been disproportionately affected by both vaccines.
The blood-clotting disorder is called cerebral venous sinus thrombosis, and it was only reported in individuals who also had low levels of blood platelets, a condition called thrombocytopenia.
The Johnson & Johnson and AstraZeneca COVID-19 vaccines are both adenovirus viral vector-based vaccines with similar mechanism.
The six cases in the U.S. were in women between the ages of 18 and 48. Women have been disproportionately affected by both vaccines.
The blood-clotting disorder is called cerebral venous sinus thrombosis, and it was only reported in individuals who also had low levels of blood platelets, a condition called thrombocytopenia.
The Johnson & Johnson and AstraZeneca COVID-19 vaccines are both adenovirus viral vector-based vaccines with similar mechanism.
No thrombotic syndrome cases have been reported in people who have received either the Pfizer Inc. PFE, or Moderna Inc. MRNA, mRNA vaccines.
Is it necessary for young people to be vaccinated at all? Listen to the science.
No comments:
Post a Comment